Blood‐based biomarkers enrich for amyloid positive participants, reducing patient burden in PROGRESS‐AD, a phase 2 clinical trial for early Alzheimer's disease

Utilizing blood-based biomarkers significantly decreased the number of participants required to have unnecessary CSF or PET testing. Limitations of this study are incomplete confirmatory results for amyloid negative individuals, regional PET/CSF confirmatory test bias, and the delay between historical result and blood biomarker testing. Including blood-based biomarkers in screening can reduce participant burden, enhance access and enrollment and improve clinical trial design.